The company informed the CHMP that there are no consequences for patients currently included in clinical trials with Cerepro.
Ettevõte teavitas inimtervishoius kasutatavate ravimite komiteed, et tagajärjed Cerepro kliinilistesse uuringutesse hetkel kaasatud patsientidele puuduvad.